ArticlePloS one2026
Modifiable determinants of adherence to tyrosine kinase inhibitors in classical myeloproliferative neoplasms: A mixed-methods systematic review protocol.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNon-receptor Tyrosine kinase inhibitors (TKIs), such as ABL1 and JAK inhibitors, are central to the management of classical myeloproliferative neoplasms (MPNs), yet non-adherence remains frequent and is associated with poorer clinical outcomes. Although adherence-related factors have been explored, the evidence has not been systematically synthesised within a behavioural theory framework to guide the development of effective interventions. This review aims to synthesise evidence on modifiable determinants (barriers and facilitators) influencing adherence to TKI therapy in adults with classical MPNs, and to classify these determinants using the Theoretical Domains Framework (TDF) and Capability, Opportunity, Motivation-Behaviour (COM-B) model.
methodsThis is a mixed-methods systematic review protocol. We will search MEDLINE/PubMed, Embase, CINAHL, LILACS, PsycINFO, and the Cochrane Library from inception to the present, without date restrictions, alongside grey literature sources (OpenGrey, WorldCat, and Google Scholar). Key terms will include myeloproliferative neoplasms, chronic myeloid leukaemia, polycythaemia vera, primary myelofibrosis, tyrosine kinase inhibitors, imatinib, dasatinib, ruxolitinib, and medication adherence. Two reviewers will independently screen studies, extract data, and assess methodological quality using design-appropriate appraisal tools. Quantitative findings will be synthesised narratively and meta-analysed where appropriate. Effect estimates from quantitative studies and qualitative findings (including participant quotations and interpretative data) will be mapped to TDF domains and COM-B components. A mixed-methods synthesis will integrate and triangulate determinants across study designs. Confidence in the evidence will be assessed using GRADE (quantitative) and CERQual (qualitative).
conclusionThis review will provide a theory-informed synthesis of modifiable determinants of TKI adherence in classical MPNs, supporting the identification of targets for future adherence-enhancing interventions.
trial registrationSystematic review registration: PROSPERO registration number: CRD42024512635.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.